Moderna Inc. Stock
€36.44
Your prediction
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Not a member yet? Sign up for free!
Financial data and news for Moderna
sharewise wants to provide you with the best news and tools for Moderna, so we directly link to the best financial data sources.
Financials
News
3 ETFs Catapulting Beyond the S&P to Start the Year
About a month into the new year, exchange-traded funds (ETFs) are beginning to build up enough of a performance record for 2026 to potentially differentiate themselves from the broader market. The
Moderna Pops 17%—Is There Life in MRNA, Down 90% from COVID High?
In a blast from the past, COVID-19 vaccine developer Moderna (NASDAQ: MRNA) just made headlines in 2026. Shares jumped up more than 17% on Jan. 13, Moderna's largest single-day up-move in over
This Stock Is Already Up 58% This Year. Is It a Buy?
The past few years have been challenging for Moderna (NASDAQ: MRNA) as the biotech has failed to maintain strong revenue growth from its coronavirus vaccine. The company's shares have significantly
Why Moderna Stock Surged Today
Shares of Moderna (NASDAQ: MRNA) popped on Wednesday after the biotech leader announced positive clinical trial results for its experimental skin cancer vaccine, developed with healthcare giant
Forget Moderna Stock, This is a Much Better Buy
Investors flocked to Moderna (NASDAQ: MRNA) stock in the early days of the pandemic for one big reason: The company sold one of the world's most-needed products, a coronavirus vaccine. The vaccine
Down 80%, Should You Buy the Dip on Moderna?
Moderna (NASDAQ: MRNA) was once the stock everyone rushed to add to their portfolios. That's because the company made the world's most sought-after pharma product: the coronavirus vaccine.
During
Telemark Asset Management Builds Position in Beaten-Down Biotech Stock.
Telemark Asset Management, LLC established a new position in Moderna (NASDAQ:MRNA), acquiring 500,000 shares valued at approximately $12.91 million as of September 30, 2025, according to a November
Prediction: Moderna Will Soar Over the Next 5 Years. Here's 1 Reason Why.
Long gone are the days when Moderna (NASDAQ: MRNA) would generate over $18 billion in annual sales from its COVID-19 vaccine. Over the past couple of years, the company's revenue and earnings have
Should You Buy Moderna Right Now?
Has Moderna (NASDAQ: MRNA) finally bottomed out? You may be asking that yourself right now, as shares in the biotech company have held steady at around $25 per share over the past six months.
These 3 Beaten-Down Healthcare Stocks Could Have Farther to Fall
"Buying the dip" can be a double-edged sword for investors. Sometimes they can seize the opportunity by purchasing an oversold stock, but other times, that stock is trending lower for a good reason
Why Moderna Might Be a One-Hit Wonder
Can you believe that Moderna (NASDAQ: MRNA) was once worth more than $195 billion in 2021? Back then, the business looked on track to be the next big healthcare company.
Then, demand for its
2 Beaten-Down Stocks to Buy and Hold for a Decade
Over the past couple of years, Moderna (NASDAQ: MRNA) and Regeneron Pharmaceuticals (NASDAQ: REGN) have encountered company-specific headwinds that have sunk their stock prices. The former is down
Is it Time to Dump Your Shares of Moderna?
Although you may not exactly understand what Moderna (NASDAQ: MRNA) does, you probably know the company's name, given its involvement in the coronavirus pandemic. The messenger RNA technology, or
If You're in Your 30s, Consider Buying These 2 Healthcare Stocks
Investing styles tend to evolve as people age. Seniors who are already retired often look for steady, reliable, dividend-paying companies. Younger investors, on the other hand, can afford to take
The 3 Things That Matter for Moderna Now
Since hitting their peak in late 2021, Moderna's (NASDAQ: MRNA) shares are down by more than 90%. The biotech company gained recognition by developing one of the leading coronavirus vaccines on the